Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis

Background: According to the 2023 guidelines for treating non-small-cell lung cancer (NSCLC), first-line treatment and recently developed agents for the treatment of epidermal growth factor (EGFR) mutation-positive locally advanced or metastatic NSCLC were compared in this meta-analysis. Treatment r...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wei, Miao, Julian, Wang, Ying, Xing, Wenzhong, Xu, Xiumei, Wu, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358853/
https://www.ncbi.nlm.nih.gov/pubmed/37484016
http://dx.doi.org/10.3389/fphar.2023.1212313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358853/
https://www.ncbi.nlm.nih.gov/pubmed/37484016
http://dx.doi.org/10.3389/fphar.2023.1212313

Ejemplares similares